OSI Pharmaceuticals (OSIP) - formerly Oncogene Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (149)	4/20/2002 8:21:00 PM
From: mopgcw	Read Replies (1) of 447

OSI Pharmaceuticals Registers $200M Conv Notes For Holders DOW JONES NEWSWIRES WASHINGTON -- OSI Pharmaceuticals Inc. (OSIP) registered to offer up to $200 million of its 4% convertible senior subordinated notes due 2009 on behalf of holders under a shelf registration statement released late Friday by the Securities and Exchange Commission. The registering holders originally acquired the notes on Feb. 1 in a Rule 144a private placement. OSI Pharmaceuticals won't receive any proceeds from the resale of the securities. The company also registered 4 million shares of its common stock issuable upon conversion of the notes. The notes are convertible at a conversion price of $50 a share. The Bank of New York is listed as trustee for the notes. OSI Pharmaceuticals, of Uniondale, N.Y., is a drug discovery company.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next